ScholarIQanswers from OpenAlex & ORCID
Hiromichi Ebi
ResearcherPublications, citations & collaboration network
Hiromichi Ebi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hiromichi Ebi have?
ScholarIQindexed works
Hiromichi Ebi has 240 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hiromichi Ebi have?
ScholarIQcitation count
Hiromichi Ebi has 8,788 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hiromichi Ebi?
ScholarIQh-index
Hiromichi Ebi has an h-index of 42 in OpenAlex.
What is the i10-index of Hiromichi Ebi?
ScholarIQi10-index
Hiromichi Ebi has an i10-index of 77 in OpenAlex.
What is the ORCID of Hiromichi Ebi?
ScholarIQorcid
The ORCID for Hiromichi Ebi is on the source record.
What is the OpenAlex record for Hiromichi Ebi?
ScholarIQopenalex
The OpenAlex for Hiromichi Ebi is on the source record.
What are the most-cited papers on Hiromichi Ebi?
ScholarIQmost cited works
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle, Dora Dias‐Santagata, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino–Kenudson, Jeffrey A. Engelman
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki, Rui‐Hua Xu, Tae‐Woo Kim, Muhammad Ismail, Iain Tan, Kun‐Huei Yeh, Axel Grothey, S. Zhang, Joong Bae Ahn, M.Y. Mastura, Dawn Q. Chong, Liqun Chen, Scott Kopetz, Takako Eguchi-Nakajima, Hiromichi Ebi, Atsushi Ohtsu, Andrés Cervantes, Kei Muro, Josep Tabernero, Hironobu Minami, Fortunato Ciardiello, Jean‐Yves Douillard
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes, Eugene Lifshits, Hiromichi Ebi, Victor M. Rivera, William C. Shakespeare, A. John Iafrate, Jeffrey A. Engelman, Alice T. Shaw
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen Zhao, Katherine A. Cheng, Zandra E. Walton, Yuchuan Wang, Hiromichi Ebi, Takeshi Shimamura, Yan Liu, Tanya Tupper, Jing Ouyang, Jie Li, Peng Gao, Michele Sue‐Ann Woo, Chunxiao Xu, Masahiko Yanagita, Abigail Altabef, Shumei Wang, Charles Lee, Yuji Nakada, Christopher G. Peña, Yanping Sun, Yoko Franchetti, Catherine Yao, Amy Saur, Michael D. Cameron, Mizuki Nishino, D. Neil Hayes, Matthew D. Wilkerson, Patrick J. Roberts, Carrie B. Lee, Nabeel Bardeesy, Mohit Butaney, Lucian R. Chirieac, Daniel B. Costa, David M. Jackman, Norman E. Sharpless, Diego H. Castrillón, George D. Demetri, Pasi A. Jänne, Pier Paolo Pandolfi, Lewis C. Cantley, Andrew L. Kung, Jeffrey A. Engelman, Kwok‐Kin Wong
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Kenneth E. Hung, Toshi Shioda, Dora Dias‐Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino–Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman